Tarveda Therapeutics Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Tarveda Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013478
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Tarveda Therapeutics Inc (Tarveda), formerly Blend Therapeutics Inc is a biopharmaceutical company that discovers and develops miniaturized novel biologic drug conjugates. The company develops targeted anti cancer medicines for advancing the treatment for solid tumors. Its pipeline prodicts includes its lead drug candidate, BTP-114, a novel, personalized cisplatin prodrug and BTP-277 and other novel drug conjugates from the company’s proprietary Pentarin platform. Tarveda offers PEN-221 designed to treat patients with neuroendocrine cancers and small cell lung cancer, and PEN-866 for the intracellular protein HSP90, is designed to treat patients with solid tumor cancers including colorectal cancer, small cell lung cancer and sarcoma. The company operates through other pharmaceutical companies to develop its proprietary Pentarins and new miniaturized biologic drug conjugates. Tarveda is headquartered in Watertown, Massachusetts, the US.

Tarveda Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Tarveda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Tarveda Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Tarveda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Tarveda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Tarveda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Tarveda Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Tarveda Therapeutics Raises USD30 Million in Series D Financing 11
Tarveda Therapeutics Raises Additional USD12.5 Million in Venture Financing 13
Blend Therapeutics Raises USD38 Million in Series C Financing 14
Blend Therapeutics Raises USD21 Million in Extended Series B Financing 15
Blend Therapeutics Raises US$0.9 Million In Venture Financing 17
Blend Therapeutics Raises US$21 Million In Series B Financing 18
Blend Therapeutics Secures US$2.8 Million In Series A Financing 20
Licensing Agreements 21
Tarveda Therapeutics Enters into Licensing Agreement with Madrigal Pharma 21
Blend Therapeutics Enters into Licensing Agreement with Biotech Company 22
Equity Offering 23
Placon Therapeutics Spin Out from Tarveda Therapeutics 23
Tarveda Therapeutics Inc – Key Competitors 24
Tarveda Therapeutics Inc – Key Employees 25
Tarveda Therapeutics Inc – Locations And Subsidiaries 26
Head Office 26
Recent Developments 27
Corporate Communications 27
Jun 19, 2017: Tarveda Therapeutics Appoints Biotech Business Veteran Michael A. Metzger to Board of Directors 27
Jan 27, 2016: Tarveda Therapeutics Appoints Oncology Drug Development Leader Leila Alland, M.D., as Chief Medical Officer 28
Product News 29
11/22/2016: Tarveda to Present at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 29
Clinical Trials 30
Sep 29, 2016: Tarveda to Present at North American Neuroendocrine Tumor Society (NANETS) Symposium 30
Other Significant Developments 31
Jan 04, 2017: Tarveda Therapeutics Provides Year-End Update and Outlines Milestones for 2017 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
Tarveda Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Tarveda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Tarveda Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Tarveda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Tarveda Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Tarveda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Tarveda Therapeutics Raises USD30 Million in Series D Financing 11
Tarveda Therapeutics Raises Additional USD12.5 Million in Venture Financing 13
Blend Therapeutics Raises USD38 Million in Series C Financing 14
Blend Therapeutics Raises USD21 Million in Extended Series B Financing 15
Blend Therapeutics Raises US$0.9 Million In Venture Financing 17
Blend Therapeutics Raises US$21 Million In Series B Financing 18
Blend Therapeutics Secures US$2.8 Million In Series A Financing 20
Tarveda Therapeutics Enters into Licensing Agreement with Madrigal Pharma 21
Blend Therapeutics Enters into Licensing Agreement with Biotech Company 22
Placon Therapeutics Spin Out from Tarveda Therapeutics 23
Tarveda Therapeutics Inc, Key Competitors 24
Tarveda Therapeutics Inc, Key Employees 25

★海外企業調査レポート[Tarveda Therapeutics Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • BMG Resources Ltd (BMG):企業の財務・戦略的SWOT分析
    Summary BMG Resources Ltd (BMG), formerly known as Brazilian Metals Group Ltd, is a mineral exploration company that explores lithium brine in Chile. The company's portfolio includes exploration tenements located in the Republic of Cyprus. Its product portfolio include nickel, gold, copper, cobalt, …
  • Aquion Energy Inc:電力:M&Aディール及び事業提携情報
    Summary Aquion Energy Inc (Aquion) is a diversified company. The company manufactures and markets saltwater batteries. It offers bulk energy storage modules, M-line battery modules, and S-line battery stacks. Aquion utilizes Aqueous Hybrid Ion battery technology to provide long-duration energy stora …
  • Novartis AG (NOVN):企業の財務・戦略的SWOT分析
    Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • MannKind Corp (MNKD)-製薬・医療分野:企業M&A・提携分析
    Summary MannKind Corp (MannKind) is a biopharmaceutical company that discovers, develops and commercializes therapeutic products to treat diseases such as diabetes. The company’s lead product, Afrezza is a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type …
  • Northwest Pipe Co (NWPX):企業の財務・戦略的SWOT分析
    Northwest Pipe Co (NWPX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Fagron NV (FAGR)-医療機器分野:企業M&A・提携分析
    Summary Fagron NV (Fagron), formerly Arseus NV is a provider of pharmaceutical compounding solutions. The company provides compounding essentials, trademarks, and pharma services to pharmacies, hospitals and clinics. Its compounding services provide customized pharmaceutical products for specific pa …
  • DBK Pharmaceutical:製薬・医療:M&Aディール及び事業提携情報
    Summary DBK Pharmaceutical (DBK Pharma) is a pharmaceutical company that develops, manufactures and markets pharmaceutical, herbal brands, food supplements, cosmetics and veterinary products. The company’s pharmaceutical products include chitocal capsule, debeskon, rentensar tablets, pressothioval, …
  • Biotest AG (BIO):企業の財務・戦略的SWOT分析
    Biotest AG (BIO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • PetroChina Company Limited:企業の戦略・SWOT・財務分析
    PetroChina Company Limited - Strategy, SWOT and Corporate Finance Report Summary PetroChina Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Acer Inc (2353):企業の財務・戦略的SWOT分析
    Acer Inc (2353) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Corby Spirit and Wine Limited:企業の戦略・SWOT・財務分析
    Corby Spirit and Wine Limited - Strategy, SWOT and Corporate Finance Report Summary Corby Spirit and Wine Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • FedEx Corporation:企業の戦略・SWOT・財務情報
    FedEx Corporation - Strategy, SWOT and Corporate Finance Report Summary FedEx Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Credit Andorra SA:企業の戦略・SWOT・財務分析
    Credit Andorra SA - Strategy, SWOT and Corporate Finance Report Summary Credit Andorra SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Entera Bio Ltd (ENTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Entera Bio Ltd (Entera Bio) is a clinical-stage biopharmaceutical company that provides development and commercialization of a novel drug delivery platform for bone healing. The company develops novel drug delivery platform for oral delivery of large molecule protein active pharmaceutical in …
  • Cathay Pacific Airways Limited:戦略・SWOT・企業財務分析
    Cathay Pacific Airways Limited - Strategy, SWOT and Corporate Finance Report Summary Cathay Pacific Airways Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Albemarle Corporation:企業の戦略・SWOT・財務分析
    Albemarle Corporation - Strategy, SWOT and Corporate Finance Report Summary Albemarle Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Agilent Technologies Inc (A)-製薬・医療分野:企業M&A・提携分析
    Summary Agilent Technologies Inc (Agilent) is a provider of instruments, reagents, software, services and consumables for comprehensive laboratory workflow. Its product portfolio comprises atomic absorption systems, bioanalyzers, gene expression microarrays and automation systems, among others. The …
  • Mount Tam Biotechnologies Inc (MNTM):企業の財務・戦略的SWOT分析
    Summary Mount Tam Biotechnologies Inc (Mount Tam Biotechnologies), a subsidiary of TabacaleraYsidron Inc is a provider of pharmaceutical products that offers development and commercialization of medical compounds for autoimmune diseases. The company’s lead product candidate TAM-0, a rapamycin analog …
  • Quebecor Inc (QBR.B):企業の財務・戦略的SWOT分析
    Quebecor Inc (QBR.B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • EMIS Group plc (EMIS):企業の財務・戦略的SWOT分析
    Summary EMIS Group Plc (EMIS), formerly Egton Medical Information Systems Ltd, is a provider of information technology and related services. The company provides electronic patient record systems and software solutions such as EMIS web, used for clinical services; EMIS IQ for data extraction; and sy …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆